Pacgen Biopharmaceuticals Corporation is a life sciences company focused on the development of novel therapeutics for the treatment of infectious and inflammatory diseases.
The Company’s lead product, PAC-113, is an anti-fungal in a Phase II program for the treatment of oral Candidiasis. Pacgen recently reported positive results for PAC-113 and initiated a Phase IIb in November 2007. The Company expects to receive the results for this Phase IIb study in mid 2008.We also have an early stage research program focused on a peptide therapeutic, PAC-G31P, which is being investigated in preclinical studies for its potential to treat inflammatory disease.
Pacgen holds the rights to 20 patents and 17 patent applications in the United States and other jurisdictions relating to products in their development pipeline.
Pacgen was founded in 2004 and listed on the Toronto Venture Stock Exchange in December 2006 under the symbol TSX-V:PGA. The Company raised CDN $7M in its initial public offering to support the advancement of its programs. The Company’s operating facility is located in Vancouver, British Columbia, Canada.
Upcoming Key Events
- Report new data supporting PAC-113 potential
- Report on PAC-G31P program and partnering strategy
- Build pipeline through acquisition or in-license
Accomplishments
- Recruited over 200 patients into the Phase IIb dose ranging trail of PAC-113 for the treatment of oral Candidiasis (Q108)
- Completed private placement financing C$903K (Q108)
- Initiated PAC-113 Phase IIb dose-ranging clinical trial in the treatment of oral Candidiasis (Q307)
- Presented poster entitled “Evaluation of a New host Derived Synthetic Anti-fungal Peptide (PAC-113) in the treatment of Oral Candidiasis” at the 5th Annual ACCP Meeting (Q307)
- Filed a new patent application containing claims covering the findings of the optimized formulation of PAC-113 with the US Patent and Trademark Office. (Q207)
- Reported positive proof of efficacy results from Phase I/IIa trial of PAC-113 in treatment of oral Candidiasis (Q207)
- Recruited over 100 patients into the Phase I/IIa clinical study of PAC-113 for the treatment of oral Candidiasis (Q207)
- Appointed Mr. DuFresne as new President & CEO (Q107)
- Completed IPO and raised ~ C$7.1M (Q406)
- Expand Pacgen product pipeline through the completion of an acquisition or a product in-license
- Complete financing to support advancement of PAC-113 into Phase II, PAC-G31P preclinical program and new products in pipeline
- Acquired an early stage drug candidate and C$1.5M working capital from IL Therapeutics Inc. (Q206)
- Appointed Ms. Yip as CFO (Q206)
- Initiated PAC-113 Phase I/IIa study in oral Candida (Q106)
- In-licensed PAC-113 from Demegen Inc. (Q105)
- Completed private financings C$1.4M (Q405)